Financial Performance - For the six months ended June 30, 2024, the Group's revenue amounted to HK$22.0 million, a decrease of HK$1.3 million or 5.6% from HK$23.3 million in the corresponding period last year[7]. - The Group's gross profit was HK$6.8 million, representing an increase of HK$1.9 million or 38.8% compared to HK$4.9 million for the same period last year, with a gross profit margin increase of 9.7 percentage points to 30.8%[7]. - The overall loss attributable to owners of the Company was HK$25.4 million, a decrease of HK$4.3 million compared to a loss of HK$29.7 million for the same period last year[9]. - Revenue for the six months ended June 30, 2024, was HK$22,007,000, a decrease of 5.4% compared to HK$23,259,000 in 2023[54]. - Gross profit increased to HK$6,782,000, up 38.1% from HK$4,906,000 in the previous year[54]. - Loss before income tax improved to HK$25,429,000, a reduction of 14.8% from HK$29,673,000 in 2023[54]. - Basic and diluted loss per share improved to HK(2.63) cents from HK(3.36) cents in the previous year[54]. - The consolidated loss before income tax for the six months ended June 30, 2024, was HK$25,429,000, compared to a loss of HK$29,673,000 for the same period in 2023, indicating an improvement of approximately 14.8%[77]. Revenue Breakdown - Revenue from the Medical Products Business was stable at HK$16.3 million, compared to HK$16.4 million in the same period last year, accounting for 74.2% of the Group's total revenue[9]. - Revenue from the Plastic Products Business decreased to HK$Nil million, down from HK$0.6 million in the same period last year, accounting for 0% of the Group's total revenue[12]. - Revenue from external customers for the Medical Devices Business was HK$16,327,000 for the six months ended 30 June 2024[67]. - The Money Lending Business generated revenue of HK$5,680,000 during the same period[67]. - Total reportable segment revenue for the Group was HK$22,007,000 for the six months ended 30 June 2024[67]. Expenses and Costs - Other losses during the period amounted to HK$22.9 million, compared to a loss of HK$20.3 million in the corresponding period of 2023[7]. - Distribution costs decreased by HK$0.5 million to HK$2.2 million during the period under review[9]. - Administrative expenses decreased by HK$4.2 million to HK$5.9 million, representing a decrease of 41.6% over the corresponding period last year[9]. - Finance costs amounted to HK$1.2 million, down from HK$1.4 million in the same period last year[9]. - The cost of inventories recognized as expenses for the six months ended June 30, 2024, was HK$15,225,000, a decrease from HK$17,908,000 in 2023, indicating a reduction of approximately 15%[83]. Investment and Assets - The Group recorded a net unrealised and realised loss of HK$22.9 million from its securities investment, compared to a loss of HK$11.0 million for the same period last year[19]. - As of 30 June 2024, the outstanding principal and interest amount of loan receivables was HK$147.0 million, down from HK$153.5 million as of 31 December 2023[16]. - As of June 30, 2024, the Group's consolidated net asset was approximately HK$35.9 million, a decrease of approximately HK$25.5 million from HK$61.4 million as of December 31, 2023[30]. - The Group's total cash and bank balances amounted to approximately HK$4.6 million as of June 30, 2024, down HK$3.1 million from HK$7.7 million as of December 31, 2023[30]. - The Group's gearing ratio increased to 73.2% as of June 30, 2024, compared to 37.8% as of December 31, 2023[30]. Share Options and Capital - The Share Option Scheme was adopted on June 30, 2015, to incentivize eligible participants for their contributions to the Group[45]. - The maximum number of shares that may be issued upon the exercise of all share options under the Share Option Scheme is capped at 10% of the issued share capital of the Company at the time of approval[46]. - The exercise price of share options must be at least the highest of the closing price on the grant date, the average closing price for the five business days preceding the grant date, or the nominal value of a share[46]. - The Company has authorized a maximum of 48,377,589 share options under the Share Option Scheme as of June 30, 2022[48]. - The issued and fully paid share capital as of June 30, 2024, is 967,551,792 shares, totaling HK$48,378,000[106]. Corporate Governance - The Company has complied with all code provisions of the Corporate Governance Code for the six months ended June 30, 2024[53]. - The Audit Committee has reviewed the accounting principles and practices adopted by the Group and discussed financial reporting matters for the six months ended June 30, 2024[53]. - The Company has confirmed full compliance with the Model Code for securities transactions by Directors during the six months ended June 30, 2024[53]. Employee and Management - The Group has 30 employees as of June 30, 2024, with remuneration largely based on performance and industry practices[39]. - The remuneration of key management personnel for the six months ended June 30, 2024, was HK$408,000, a decrease from HK$426,000 in the same period of 2023[109].

Financial Performance - The total revenue of AMCO United Holding Limited decreased by HK$32.2 million or 48.4%, from HK$66.5 million in 2022 to HK$34.3 million in 2023[13]. - The loss for the year improved significantly to HK$2.75 million in 2023 from HK$104.25 million in 2022[6]. - Overall loss attributable to owners of the Company was HK$2.8 million, a significant decrease of 97.3% from a loss of HK$104.3 million in 2022[31]. - The Group recorded a realized and unrealized loss of HK$8.5 million in 2023 from changes in the fair value of held-for-trading investments, compared to a loss of HK$4.6 million in 2022[153]. - The segment loss from Securities Investment amounted to HK$8.8 million in 2023, an increase from a loss of HK$4.6 million in 2022[153]. Equity and Assets - Equity attributable to owners of the Company increased to HK$61.36 million in 2023 from HK$18.59 million in 2022[6]. - The Group's consolidated net assets increased to HK$61.4 million as of December 31, 2023, up from HK$18.6 million as of December 31, 2022[165]. - The Group's total cash and bank balances amounted to HK$7.7 million as of December 31, 2023, an increase of HK$4.0 million from HK$3.7 million as of December 31, 2022[169]. - As of December 31, 2023, the carrying amount of the plant and machinery is approximately HK$Nil, down from HK$1.1 million in 2022[98]. Financial Ratios - The current ratio improved to 2.2 in 2023 from 1.7 in 2022, indicating better short-term financial health[6]. - The total debt to total assets ratio decreased to 0.6 in 2023 from 0.9 in 2022, reflecting reduced leverage[6]. - The Group's gearing ratio improved to 37.8% as of December 31, 2023, compared to 277.1% as of December 31, 2022[174]. Revenue Breakdown - Revenue from medical products dropped by 59.7% or HK$32.5 million, accounting for 63.9% of the Group's total revenue in 2023[37]. - Revenue from the Building Contract Works Business decreased due to fewer contract awards in both public and private sectors[17]. - Revenue from the Medical Products Business totaled HK$21.9 million for the year ended December 31, 2023, with Customer A contributing HK$10.1 million and Customer B contributing HK$8.3 million[112]. - Revenue from Plastic Products decreased by 45.5% to HK$0.6 million, accounting for 1.8% of the Group's total revenue, with a segment loss of approximately HK$829,000[118][123]. Business Segments - The Money Lending Business generated stable income for the Group in 2023, contrasting with losses in the Securities Investment segment[18]. - The Building Contract Works Business generated no revenue for the year, a decrease of HK$2.7 million or 100%, resulting in a segment loss of HK$1.0 million[120][124]. - Loan interest income from Money Lending increased by 8.3% to HK$11.8 million, accounting for 34.3% of the Group's total revenue, with a segment profit of HK$14.7 million[127]. Cost Management - Distribution and administrative expenses decreased by HK$11.0 million or 44.0% to HK$14.0 million compared to HK$25.0 million in 2022[30]. - The Group is implementing strict cost control measures and streamlining business processes to maintain competitive advantages[14]. Credit and Risk Management - The expected credit loss (ECL) provision was reversed by approximately HK$7.9 million in 2023, compared to a provision of approximately HK$76.3 million in 2022[31]. - The credit loss rate applied for loan receivables was 47.1% in 2023, slightly up from 46.3% in 2022[36]. - JS Finance has adjusted its lending strategy to enhance borrower requirements, including the need for asset or income proof to lower the default ratio[132]. Investment Strategy - The Group intends to diversify its investment portfolio to reduce concentration and investment risks due to recent market volatility[154]. - The Group will maintain a prudent investment attitude and develop strategies to improve capital usage efficiency and generate additional returns on idle funds[154]. Operational Efficiency - The Group will focus on reallocating assets and resources to adapt to changing market conditions and enhance operational efficiency[23]. - The Group emphasizes just-in-time production to minimize storage costs and the risk of obsolete stock, adjusting production volumes and pricing strategies based on actual market demand[92]. Employee Management - As of December 31, 2023, the group has 30 employees, maintaining the same number as the previous year[183]. - Employee compensation is determined based on performance and experience, with benefits including salary, insurance, mandatory provident fund, and stock option plans[183]. Corporate Governance - The company has complied with all code provisions of the Corporate Governance Code throughout the year ended December 31, 2023, with certain disclosed deviations[200].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 1 | | | 二零二三年 | 二零二二年 | | --- | --- | --- | --- | | | 附註 | 千港元 | 千港元 | | | | | （經重列） | | 除所得稅前虧損 | 7 | (1,713) | (104,293) | | 所得稅開支 | 8 | – | – | | 持續經營業務之年度虧損 | | (1,713) | (104,293) | | 已終止經營業務 | | | | | 已終止經營業務之年度（虧損）╱收益 | 9 | (1,040) | 42 | | 本公司擁有人應佔年度虧損 | | (2,753) | (104,251) | | 其他全面虧損 | | | | | 其後可重新分類至損益之項目： | | | | | 換算海外業務產生之匯兌差額 | | – | (1,193) | | 出售附屬公司後重新分類匯兌差額 ...

(Stock Code 股份代號 : 630) (Incorporated in Bermuda with limited liability) （於百慕達註冊成立之有限公司） AMCO UNITED HOLDING LIMITED 2023 INTERIM REPORT 中期報告 * For identification purposes only 僅供識別 Contents 目錄 | Management Discussion and Analysis | 管理層討論及分析 | 2 | | --- | --- | --- | | Corporate Governance and Other Information | 企業管治及其他資料 | 13 | | Interim Condensed Consolidated Statement of Profit or Loss and | 簡明綜合中期損益及其他全面收益表 | 21 | | Other Comprehensive Income | | | | Interim Condensed Consolidated Statement of Financia ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 二零二三年中期業績公告 雋泰控股有限公司（「本公司」）董事會（「董事會」）欣然宣佈本公司及其附屬公司 截至二零二三年六月三十日止六個月的未經審核綜合業績。本公告列載本公司二 零二三年中期報告的全文，並符合香港聯合交易所有限公司證券上市規則（「上市 規則」）中有關中期業績初步公告附載的資料要求。 為及代表董事會 雋泰控股有限公司 主席兼董事總經理 張亨鑫 香港，二零二三年八月二十八日 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 有關截至二零二二年報之 補充公告 茲提述雋泰控股有限公司（「本公司」）截至二零二二年十二月三十一日止年度之 年報（「二零二二年報」）。除另行界定外，本公告所用詞彙與二零二二年報內所界 定者具相同涵義。 除二零二二年報中的董事會報告當中「購股權計劃」一節及綜合財務報表附註29 所披露的內容外，本公司欲提供以下有關購股權計劃的額外資料。 截至二零二二年一月一日及二零二二年十二月三十一日，根據計劃授權授出及根 據購股權計劃可發行的購股權總數分別為48,377,589份及48,377,589份。購股權計劃 並無設定服務提供者分項限額。 ...

AMCO UNITED HOLDING LIMITED (Stock Code 股份代號 : 630) (Incorporated in Bermuda with limited liability) （於百慕達註冊成立之有限公司） 2022 ANNUAL REPORT 年 報 * For identification purposes only 僅供識別 AMCO UNITED HOLDING LIMITED 雋泰控股有限公司 ANNUAL REPORT 2022 年 報 Contents 目錄 | FINANCIAL HIGHLIGHTS | 財務摘要 | 2 | | --- | --- | --- | | CORPORATE INFORMATION | 公司資料 | 3 | | CHAIRMAN'S STATEMENT | 主席報告 | 5 | | MANAGEMENT DISCUSSION AND ANALYSIS | 管理層討論及分析 | 8 | | PROFILE OF DIRECTORS AND SENIOR MANAGEMENT | 董事及高級管理人員簡介 | 21 | | CORPORATE ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 截至二零二二年十二月三十一日止年度之業績公告 業績 雋泰控股有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，本公司及其附 屬公司（以下統稱為「本集團」）截至二零二二年十二月三十一日止年度經審核綜 合業績連同去年之比較數字如下。 綜合損益及其他全面收益表 截至二零二二年十二月三十一日止年度 二零二二年 二零二一年 附註 千港元 千港元 收入 5 67,159 71,891 銷售及服務成本 (52,442) (57,776) 毛利 14,717 14,115 其他收入及其他收益或虧損 6 (16,341) 680 分銷成本 (1,626) (718) 行政開支 (27,223) (14,789) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 補充公告 有關截至二零二一年十二月三十一日止年度之年報 謹此提述雋泰控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）日期為 二零二二年三月三十一日及於二零二二年四月二十八日刊發於香港聯合交易所有 限公司及本公司網站之截至二零二一年十二月三十一日止年度之年報（「年報」）。 除另有界定者外，本公告所用之詞彙與年報所界定者具有相同涵義。 除年報所披露之資料外，本公司謹此向股東及公眾人士提供有關年報之額外資料 如下。 放貸 本集團的放貸業務由本公司之一間間接全資附屬公司建信財務有限公司（「建信財 務」，為香港法例第163章《放債人條例》項下香港的一名持牌放債人）經營。本集 團透過使用本集團的內部資源向客戶（包括個人、私營及上市公司）提供貸款賺取 利息收入。客戶通常自本集團的業務網絡及關係（包括但不限於客戶及供應商）轉 介而來。於向潛在客戶授出貸款前，本 ...

Revenue and Profitability - For the six months ended June 30, 2021, the Group's revenue increased by HK$2.1 million or 7.6% to HK$29.8 million compared to HK$27.7 million in the same period last year, primarily driven by the Medical Products Business[7]. - Gross profit rose by HK$1.2 million or 15.4% to HK$9.0 million, with a gross profit margin increase of 2.3 percentage points to 30.5% from 28.2% in the previous year[8]. - The Medical Products Business revenue surged by HK$7.9 million or 75.2% to HK$18.4 million, accounting for 61.6% of the Group's total revenue for the period[16]. - The overall loss attributable to owners of the Company decreased by HK$10.6 million or 89.8% to HK$1.2 million compared to a loss of HK$11.8 million in the same period of 2020[15]. - Revenue for the six months ended 30 June 2021 was HK$29,845,000, representing an increase of 7.8% compared to HK$27,668,000 for the same period in 2020[134]. - Gross profit for the same period was HK$9,089,000, up from HK$7,792,000, indicating a gross profit margin improvement[134]. - Loss for the period narrowed to HK$1,245,000 from HK$11,810,000 in the previous year, reflecting a significant reduction in losses[134]. - Total comprehensive loss attributable to owners of the Company was HK$2,004,000, compared to HK$11,810,000 in the prior year[134]. Business Segments Performance - The Plastic Products Business revenue increased by HK$2.8 million or 140% to HK$3.0 million, representing 10.1% of the Group's total revenue[23]. - Revenue from the Building Contract Works Business decreased by HK$8.9 million or 76.1% to HK$2.8 million for the six months ended 30 June 2021, contributing 9.4% of the Group's total revenue[26]. - The Money Lending Business recorded loan interest income of HK$5.6 million, an increase of HK$0.4 million or 7.7%, accounting for 18.9% of the Group's total revenue[30]. - Segment profit for the Medical Products Business increased to HK$0.4 million from HK$0.1 million in the previous year, reflecting improved sales orders[21]. - The segment loss for the Building Contract Works Business decreased by HK$2.0 million or 60.6% to HK$1.3 million for the six months ended 30 June 2021[26]. - The segment profit from the Money Lending Business amounted to HK$0.6 million, up from HK$0.4 million in the previous year[30]. - Medical Devices Business generated revenue of HK$18,380,000, while the Money Lending Business contributed HK$5,631,000 for the six months ended June 30, 2021[158]. - Reportable segment profit for the six months ended June 30, 2021, was HK$11,189,000, compared to a loss of HK$4,314,000 in the same period of 2020[178]. Financial Position and Liquidity - As of 30 June 2021, the Group's consolidated net asset was approximately HK$130.1 million, a decrease of approximately HK$2.0 million compared to HK$132.1 million as at 31 December 2020[55]. - The Group's current ratio and quick ratio were both 2.2 as of June 30, 2021, down from 3.8 as of December 31, 2020, reflecting a decline in liquidity[59]. - The outstanding principal and interest amount of loan receivables was HK$136.3 million as of 30 June 2021, slightly up from HK$135.5 million at the end of 2020[30]. - Cash and cash equivalents decreased to HK$3,830,000 as of 30 June 2021, down from HK$27,663,000 at the beginning of the year[143]. - The Group's gearing ratio was 22.0% as of June 30, 2021, compared to 22.7% as of December 31, 2020, indicating a slight decrease in leverage[59]. - The Group will focus on maintaining liquidity by effectively managing working capital and controlling costs amid economic uncertainties[49]. Cost Management - Distribution costs increased significantly by HK$3.42 million to HK$3.43 million, while administrative expenses decreased by HK$1.4 million or 7.7% to HK$16.8 million[14]. - Administrative expenses decreased to HK$16,788,000 from HK$18,199,000, showing cost control efforts[134]. - Staff costs, including directors' emoluments, amounted to HK$2,543,000 for the first half of 2021, down from HK$5,032,000 in 2020, reflecting a decrease of approximately 49.7%[186]. - The cost of services recognized as expenses decreased to HK$4,964,000 in 2021 from HK$10,360,000 in 2020, reflecting a decline of about 52%[186]. Investment and Market Strategy - The Group intends to diversify its investment portfolio to reduce concentration and investment risks in light of recent market volatility[36]. - The Group aims to optimize its business portfolio to adapt to changing business climates and explore potentially profitable opportunities for sustainable growth[53]. - The Group is focusing on streamlining and outsourcing business processes, implementing strict cost control, and exploring potential business opportunities to expand its customer base[21]. - The Group will continue to focus on tendering for higher-margin projects in both public and private sectors to improve business results[29]. Corporate Governance and Compliance - The company has complied with all code provisions of the Corporate Governance Code for the six months ended June 30, 2021[121]. - All directors confirmed full compliance with the Model Code for securities transactions during the six months ended June 30, 2021[121]. - The roles of Chairman and Managing Director are combined, with Mr. Zhang Hengxin holding both positions, which the company believes is in the best interest of shareholders[121]. Share Option Scheme - The Company adopted a Share Option Scheme on June 30, 2015, approved by shareholders, to grant share options as incentives for contributions to the Group[74]. - The maximum number of shares that may be issued upon exercise of all share options under the Share Option Scheme must not exceed 10% of the issued share capital on the date of approval[80]. - The Share Option Scheme is valid for ten years and will expire at the close of business on June 29, 2025[81]. - The Company was authorized to refresh the scheme mandate limit to issue a maximum of 241,887,948 share options under the Share Option Scheme at the annual general meeting held on June 29, 2021[82]. Future Outlook - The year 2021 is expected to remain challenging due to the impact of COVID-19 and economic slowdowns, prompting the Group to modify its business strategies accordingly[48]. - The Directors noted that the future performance of the Group's investments will be volatile and significantly affected by the overall economic environment and market conditions[45].